AI can augment oncology nursing through symptom triage support, trial matching, care plan personalization, pharmacogenomics ...

Learn the risk factors, symptoms and screening options tied to colorectal cancer as cases continue rising among younger ...

Ongoing annual imaging of the remaining breast, plus peer navigation and patient self-advocacy, are framed as practical ...

Some patients treated with immunotherapy may develop lifelong endocrine conditions requiring ongoing hormone replacement, ...

Researchers at Moffitt Cancer Center are studying a new topical therapy called DYV800 that may help the immune system fight ...

New research suggests biologic aging and neighborhood-related stress may affect how aerobic exercise influences cognition after breast cancer treatment.

FDA accelerated approval covers relapsed/refractory MCL after ≥2 lines including a BTK inhibitor, positioning sonrotoclax as ...

Neoadjuvant Enhertu→THP improved pCR to 67.3% vs 56.3% with AC→THP in stage II–III high-risk HER2-positive disease (DESTINY-Breast11). Adjuvant Enhertu achieved 3-year IDFS 92.4% vs 83.7% with T-DM1 ...

Veppanu represents a scientific milestone as the first-ever proteolysis-targeting chimera (PROTAC) to receive FDA approval.

Preserve muscle mass during GLP-1 therapy for cancer. Experts discuss body composition, sarcopenia, and treatment durability in oncology care. As GLP-1 receptor agonists like Ozempic and Wegovy ...

A USC study finds immunotherapy increases PAD risk by 60%. Experts advise vascular monitoring to help prevent limb loss in ...